Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies

By afschroeder • November 23, 2025

Nel AE, Luo L, Liao YP, Wang X. Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies. ACS Nano. 2025 Nov 22. doi: 10.1021/acsnano.5c14753. Epub ahead of print. PMID: 41273281.

Tags: General Internal Medicine, immune adjuvant nanocarrier, immune tolerance, immunotherapy, lipid nanoparticle, mRNA, Nano Medicine, Pancreatic ductal adenocarcinoma (PDAC), Post Doc, Publications, reprogramming, tumor microenvironment

Corrigendum to “Antibodies to angiotensin II type 1 receptor and endothelin type A receptor are associated with cytokine production enriched for type 2 immune response and antibody production in pediatric kidney transplant recipients” [American Journal of Transplantation. Volume 25, Issue 11, November 2025, Pages 2329-2344]

Pearl MH, Chen L, Grogan T, Nikfarjam N, Grimm PC, Fan C, Garro R, Tsai-Chambers E, Kirk AD, Ettenger R, Reed EF. Corrigendum to "Antibodies[...]

Monoclonal Immunotactoid Glomerulopathy Associated With Chronic Lymphocytic Leukemia: A Case Report

Badiee G, Kalantary A, Shafiei S, Hou J, Lazarus ME. Monoclonal Immunotactoid Glomerulopathy Associated With Chronic Lymphocytic Leukemia: A Case Report. Cureus. 2025 Nov 9;17(11):e96452.[...]

Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial

Fergus KB, Ross KS, Scheuner MT, Blanco AM, Tice JA, Ziv E, Shieh Y, van 't Veer L, Olopade OI, Goodman DL, Tong BS, Harvey[...]